Tue, Oct 21, 2014, 7:29 AM EDT - U.S. Markets open in 2 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • jmm138 jmm138 Sep 19, 1999 10:42 AM Flag

    Resistant Bacteria

    Of what value is antisense in the need to develop new antibiotics for resistant strains of bacteria?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There was another one yesterday at the University
      of PA hospital in Phila. Same story. The patient was
      injected with a virus that carried a gene therapy agent.
      there are 17 other patients in this trial who are doing
      OK. There was no mention of the supplier of the gene
      therapy agent, but I'm sure that it wasn't ISIP because
      they don't use viruses to transmit the drug.

    • You are exactly correct!!!! Good news seems to be coming from every direction! Hang on tight..... be ready for a major upgrade from a highly respected firm very soon.IMO Cheers everyone.

    • It's hard not to get too excited about ISIS when
      I read that more and more big pharma are focusing
      more attention on antisense technology. If 2302
      results are as good as what we have been led to believe
      and additional deals are struck with other big
      pharma(s), wall street is finally going to wake up and shoot
      this stock into the stratosphere. This could be a
      really exciting next six months for all ISIS
      shareholders. I've been patiently holding this stock for
      several years and pay off time looks very near (not that
      I will sell anytime soon).

    • I also read in 1996 about Ribozyme being capable of irreversible cleavage. Does this mean it can't turn the gene back on like Isis can?

    • RP and Novartis among others are sponsoring a
      conference on Nucleic Acid Therapeutics, scheduled for Jan.
      2000. I posted a message on it #4983 (9-10-99). It
      appears that by their sponsorship big pharmas. are
      becoming very interested. This RP endorsement can only add
      to ISIPs lead in the field. Looking forward to the
      next piece of good news. Dr. Crooke seems to be
      building a steady flow of positive news for ISIP.
      Hopefully, he is saving a blockbuster news item for the
      November cancer conference. Too bad the markets are
      jittery right now or this current news would probably
      have boosted the stock. Hopefully, next time.


      Also, heard on CNBC this a.m. that FDA is investigating
      a major production contamination problem at a large
      ABBOTT pharmaceuticals manufacturing facility. Hope they
      learn from their miscue and provide ISIP with a clean
      efficient and very reliable supply source once antisense
      hits big volume.

    • Thanks for the additional detail/links on the
      gene therapy death. As I said in my previous posts,
      gene therapy is very different from the Isis antisense
      therapeutic approach and many years behind (not to mention
      the ethical issues associated).

      This just
      reaffirms my opinion that the Isis antisense therapeutic
      approach is the best I've seen to date.

      By the way,
      the adenovirus is a type of common cold virus and is
      considered to be fairly innocuous in healthy people, but in
      sick patients, it may be a different story. That's why
      I stated before that the whole antisense viral
      vector approach may still be a long winding road before
      they really have something.

    • I saw this in the Arizona Republic today. Article
      is taken from the Washington Post. The gene therapy
      is described as the most common kind today.
      Adenovirus therapy? Here are the links. The article in the
      Phoenix paper appears to be a copy of the Washington Post
      article.

      AZ
      Republic:

      http://www.azcentral.com/news/0929gene.shtml

      Washington
      Post:

      http://www.washingtonpost.com/wp-srv/health/daily/sept99/gene29.htm

      EOM

    • Isis and Rhone-Poulenc Rorer Establish Antisense
      Target Validation
      Collaboration

      CARLSBAD,
      Calif., COLLEGEVILLE, Pa. and ANTONY, France, Sept. 29
      /PRNewswire/ -- Isis
      Pharmaceuticals (Nasdaq: ISIP) and
      Rhone-Poulenc Rorer (NYSE: RP) (RPR) announced today
      that
      they have signed a three year collaboration to assess
      genes identified within RPR's genomics
      programs
      using Isis' Antisense Target Validation technology.
      This collaboration will enable RPR to determine
      the
      function and therapeutic value of numerous novel gene
      targets and to use this information about
      gene
      function to develop pharmaceutical products. It also
      provides Isis with valuable information on
      these
      targets to assist in the development of novel antisense
      drugs. This is Isis' second target
      validation
      collaboration.

      A critical process in the development of
      novel drugs is the determination of those genes that
      play a key
      role in a disease. With the entire human
      genome expected to be sequenced by the year 2003,
      antisense
      technology can be used to provide functional data on the
      importance of a specific gene in causing or
      maintaining a
      disease. Antisense technology uses genetic sequence
      information to rapidly design
      inhibitors of any gene
      target. Because of their exquisite specificity, antisense
      inhibitors can inhibit the
      selected gene only, without an
      impact on other closely related genes. As a result,
      antisense inhibitors
      allow the identification of
      function of that single gene target more precisely than
      any other method. Isis'
      Antisense Target
      Validation program is a rapid and specific tool that
      pharmaceutical companies can use
      to help evaluate, select,
      and prioritize genes as potential drug targets.


      "RPR is committed to the identification and most
      importantly the validation of innovative new targets
      for
      drug therapies within all its disease programs," said
      Francois Meyer, Senior Vice President, Research at
      RPR.
      "We view antisense technology as an important tool to
      turn sequence information into biological
      function
      knowledge. This will facilitate the development of novel and
      innovative pharmaceutical products."

      RPR will
      provide Isis with sequence information on a number of
      novel gene targets. RPR has an option to
      expand the
      number of gene targets. Using its proprietary Rapid
      Throughput Screening (RTS) technology,
      Isis will design
      optimized antisense inhibitors for these targets. RPR will
      then use these antisense
      inhibitors to identify the
      function of the gene, its role in molecular pathways
      associated with the disease,
      and prioritize the gene
      targets for development. Isis will develop antisense
      inhibitors for the targets
      provided by RPR. RPR will pay
      Isis research fees and milestone payments based on the
      success of the
      program. Financial terms were not
      disclosed.

      "Isis is pleased to be working with
      Rhone-Poulenc Rorer. Our company shares their commitment
      to
      developing new products based on the explosion of
      information from genomics research and feel that
      the
      programs will be significantly assisted by this
      collaboration," said Stanley T. Crooke M.D., Ph.D.,
      Chairman
      and CEO of Isis. "We believe this program represents
      another step in the pharmaceutical
      industry's
      realization that antisense technology adds a new dimension to
      core drug discovery programs.
      It is our hope that
      the information gained from any important new targets
      will be mutually beneficial to
      both companies and
      add both short and long term value to this
      relationship."

      The agreement allows Isis access to
      numerous novel genes identified within the RPR portfolio
      for use in
      developing antisense products. RPR will
      utilize Isis technology to elaborate on the function of
      these
      genes. Together the information from RPR's genomics
      program with Isis' antisense capabilities
      should
      enrich both companies drug pipelines.

    • ABC news had this on the radio this morning; no
      indication of what company's drug was involved or what the
      target disease was. The story said the patient had been
      injected with gene therapy agents carried by viruses. It
      also noted this was the first recorded death from gene
      therapy. I don't beleive ISIP therapy is adminsitered by
      virus.

    • For those of you following our recent
      discussions/posts on the relative attributes of Isis' antisense
      approach vs. human gene therapy or genetic
      engineering....

      I understand a patient in an Arizona clinical trial
      receiving liver gene therapy (I don't know which company's
      trial or what compound, but will try to find out more)
      died yesterday of complications. The cause of death
      was not released.

      Maybe somone out there can
      shed more light on this.

    • View More Messages
 
ISIS
41.18+1.31(+3.29%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.